Himalaya Livline | Vol 6 | No. 5 | Sep–Dec 2023 | 11 Chronic active hepatitis DS Syrup/DS Tablet: 2 Teaspoonsful/ Tablets BID for 6 months Early cirrhotic conditions DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet TID for 6 to 12 months statin/antiretroviral treatment and chemotherapy Jaundice and anorexia during pregnancy DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 8 weeks Nonalcoholic steatohepatitis (NASH) DS Tablet: 1 to 2 Tablets BID As a supportive treatment during hemodialysis DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 3 to 4 months As an adjuvant to anticancer drugs DS Syrup/DS Tablet: 1 Teaspoonful/ Tablet BID for 4 months Dr Smita Datta, MD Consultant Physician Dosti Shoppe Link Mall Wadala East Mumbai 400037, Maharashtra India Patients with T2DM are at a high risk of developing NAFLD and other hepatic complications too. Inculcating healthy lifestyle practices such as consuming a balanced diet and engaging in regular physical activity can reduce the intrahepatic triacylglycerol level and improve glycemic control/insulin sensitivity in patients with both NAFLD and T2DM. lipoprotein particles can be observed. Further, there is always a risk of all these metabolic abnormalities translating into worse cardiovascular diseases in patients with T2DM. How do diet and lifestyle choices affect the incidence of NAFLD and T2DM?What are the dietary recommendations for managing NAFLD and T2DM? The development of NAFLD and T2DM is linked to lifestyle factors such as excess intake of unhealthy and calorie-dense foods and reduced physical activity. Maintaining a healthy body weight, to a great extent, helps in the management of NAFLD and T2DM. Consuming a balanced diet, for example, Mediterranean and other hypocaloric diets, and engaging in regular physical activity can help reduce the intrahepatic triacylglycerol level and improve glycemic control/insulin sensitivity in patients with both NAFLD and T2DM. Also, patients with NAFLD must avoid excess alcohol consumption, as it increases the risk of disease progression. Doctor, what medication do you prescribe for managing NAFLD in patients with T2DM? How has it benefitted them? I have found Liv.52 DS to be very useful in the management of liver disorders. Liv.52 DS, a hepatospecific formulation from Himalaya Wellness Company, is specifically designed for the treatment and management of liver disorders. In NASH and liver diseases caused by diabetes, Liv.52 DS decreases the uptake of FFAs by the hepatocytes and helps reduce fat deposition in the hepatocytes. Liv.52 DS promotes the production of new proteins responsible for the transportation of glucose into the cells, and thus, increases glucose uptake and reduces IR. We thank our field correspondents for their input and support. Ashish Dinesh Chaubey, Regional Manager Umesh Gajanan Gawand, Pharma Sales Officer HimalayaWellness Company —Editor An Interview With Dr Smita Datta
RkJQdWJsaXNoZXIy MjAwNDg=